France· FR:68815221
KARDEGIC 300 mg, poudre pour solution buvable en sachet
A medicinal product containing dl-lysine (acétylsalicylate de), registered in France by SUBSTIPHARM, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DL-LYSINE (ACÉTYLSALICYLATE DE)
- Manufacturer
- SUBSTIPHARM
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip13340093322655830 sachet(s) papier aluminium polyéthylèneEUR 1.62
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/eedf48b4-ce07-4f0b-b4a6-57d7943744f1 GET /v1/drugs/eedf48b4-ce07-4f0b-b4a6-57d7943744f1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68815221",
"date_amm": "1989-09-25",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "DL-LYSINE (ACÉTYLSALICYLATE DE)",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution buvable",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about dl-lysine (acétylsalicylate de).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.